tbuckley/cabot-search huggingface dataset:
A rare cause of GI bleeding in a patient with cutaneous vascular malformations
Authors: Jovanna Tsoutsouki, Faidon-Marios Laskaratos, Sue Mason, Magda Smith, Leena Sinha
Journal: Gut (2016)

A 53-year-old woman with a background of chronic bronchitis was admitted with an infective exacerbation of chronic obstructive pulmonary disease. Her medical history included atrial septal defect (ASD) and ventricular septal defect (VSD) repair in childhood and a recent deep vein thrombosis, for which she was on rivaroxaban. On examination, she had multiple blue pigmented soft tissue lesions on her face, tongue, torso and hands (figures 1 and 2).



Figure 1 
A vascular blue lesion on the patient's tongue.





Figure 2 
A vascular blue lesion on the patient's eyelid.



During her admission, the patient developed melaena associated with a significant acute drop …
Sleep Duration and Injury-Related Risk Behaviors Among High School Students — United States, 2007–2013
Authors: Anne G. Wheaton, Emily O’Malley Olsen, Gabrielle F. Miller, Janet B. Croft
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Insufficient sleep is common among high school students and has been associated with an increased risk for motor vehicle crashes (1), sports injuries (2), and occupational injuries (3). To evaluate the association between self-reported sleep duration on an average school night and several injury-related risk behaviors (infrequent bicycle helmet use, infrequent seatbelt use, riding with a driver who had been drinking, drinking and driving, and texting while driving) among U.S. high school students, CDC analyzed data from 50,370 high school students (grades 9-12) who participated in the national Youth Risk Behavior Surveys (YRBSs) in 2007, 2009, 2011, or 2013. The likelihood of each of the five risk behaviors was significantly higher for students who reported sleeping ≤7 hours on an average school night; infrequent seatbelt use, riding with a drinking driver, and drinking and driving were also more likely for students who reported sleeping ≥10 hours compared with 9 hours on an average school night. Although insufficient sleep directly contributes to injury risk, some of the increased risk associated with insufficient sleep might be caused by engaging in injury-related risk behaviors. Intervention efforts aimed at these behaviors might help reduce injuries resulting from sleepiness, as well as provide opportunities for increasing awareness of the importance of sleep.
Abstract 3164: Decreased expression of GDP-mannose-4,6-dehydratase (GMD) and GDP-fucose transporter is associated with squamous histology in non-small cell lung cancers (NSCLCs)
Authors: Rio Honma, Ichiro Kinoshita, Eiji Miyoshi, Yoshihiro Matsuno, Yasushi Shimizu, Kichizo Kaga, Naoyuki Taniguchi, Hirotoshi Dosaka-Akita
Journal: Cancer Research (2011)

Abstract We have previously reported that low expression of α1,6-fucosyltransferase (FT), an enzyme for the core fucosylation of N-glycans, is significantly more prevalent in squamous cell carcinomas compared with non-squamous cell carcinomas of the lung. GMD generates GDP-fucose from GDP-mannose, and is imperative for the synthesis of all fucosylated oligosaccharides. GDP-fucose is transported into the Golgi apparatus by GDP-fucose transporter to serve as a substrate of FTs. In the present study, we examined expression of GMD and GDP-fucose transporter by immunohistochemistry in 156 surgically resected NSCLCs. High, moderate and low expression of GMD was found in 32 (20.5%), 32 (20.5%) and 92 (59.0%) NSCLCs, respectively. High/moderate, low and no expression of GDP-fucose transporter was found in 7 (4.5%), 23 (14.7%) and 126 (80.8%) NSCLCs, respectively. Low GMD expression was significantly more prevalent in tumors from men than in those from women (p = 0.02), in tumors from smokers compared with nonsmokers (p = 0.047), and in squamous cell carcinomas compared with non-squamous cell carcinomas (p = 0.0003) by the χ2 test. Multivariate logistic regression analysis for the correlation between GMD expression and various characteristics revealed a significant association between low GMD expression and squamous cell carcinomas, as compared with non-squamous cell carcinomas (low vs. moderate, p = 0.005; low vs. high, p = 0.02). Among biological characteristics of tumors studied previously in this cohort of NSCLCs, Ki-67 labeling index was significantly higher in tumors with low GMD expression than in those with high GMD expression (low vs. high, p = 0.003). Low expression of α1,6-FT was more prevalent in tumors with low GMD expression than in those with moderate or high GMD expression (p = 0.002). Low GDP-fucose transporter expression was significantly more prevalent in squamous cell carcinomas compared with non-squamous cell carcinomas (p = 0.003) by the χ2 test. GMD and GDP-fucose transporter expressions were not associated with survival. These results indicate that GMD and GDP-fucose transporter may be new markers of NSCLCs with specificity for histology. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3164. doi:10.1158/1538-7445.AM2011-3164
RM-02 * LONG-TERM SURVIVAL IN GLIOBLASTOMA PATIENTS FOLLOWING STROKE: A NON-CONSECUTIVE CASE SERIES
Authors: J. Hu, S. Phuphanich, X. Fan, J. Rudnick, R. Prasad
Journal: Neuro-Oncology (2014)

BACKGROUND: Though glioblastoma is aptly considered a diffuse invasive disease, occasionally the blood supply to the tumor falls within the vascular distribution of a single artery. In these instances, patients who suffer a stroke in the region of brain involved with tumor can sometimes survive much longer than one might expect, even in the absence of treatment. METHODS: In this single-institution retrospective analysis, we identified four non-consecutive glioblastoma patients who experienced a stroke following diagnosis. Glioblastoma pathology was confirmed by review at our institution in patients who were initially diagnosed elsewhere. RESULTS: All four patients remain alive, with ages ranging from 31 to 74. Stroke occurred following initial diagnosis in 1 patient, after first recurrence in 1 patient, and after second recurrence in 2 patients. Stroke resulted in permanent KPS decline of 10-20 in all patients. Three of the 4 patients are still progression-free; in the fourth, progression occurred outside the infarcted area. Survival from diagnosis: 48.5 mo, 103.2 mo, 108.2 mo, and 145.8 mo. Survival from stroke: 14.5 mo, 102.7 mo, 67.8 mo, and 74.0 mo, respectively. Survival since last treatment (in the 3 patients who are progression-free): 27.1 mo, 47.8 mo, 74.0 mo. CONCLUSION: Long-term survival with glioblastoma is uncommon, particularly following recurrence, and particularly in the absence of ongoing treatment. Though stroke is in general a poor prognostic factor for patients with glioblastoma, here we highlight the possibility that the acute vascular disruption that results from strokes can occasionally arrest tumor growth. Although endovascular embolization is unlikely to ever be considered an appropriate treatment for glioblastoma, these findings support the notion that vascular disrupting agents and endovascular therapies that are limited to a single vascular territory may have a role in the treatment of select patients.
Abstract 2481: Exploiting BRAF mutation for therapy of childhood low-grade astrocytoma
Authors: Aaron Kibler, Sagymbek Manap, Hemant K. Bid, Doris A. Phelps, Raushan T. Kurmasheva, Christopher E. Pelloski, Peter J. Houghton
Journal: Cancer Research (2012)

Abstract Activating mutations of BRAF (predominantly V600E) are common in low-grade astrocytomas (∼23%), and xanthoastrocytomas (60%), with or without loss of the CDKN2A locus. Surgically inoperable astrocytoma has a poor prognosis with greater than half of these patients dying from disease. We have developed two models of low-grade astrocytoma (BT-35, BT-40) by direct heterografting patient tumor into immune-deficient mice. Both tumor lines have multiple copies of BRAF, but only BT-40 has an activating mutation (V600E), and is exquisitely sensitive to the MEK inhibitor AZD6244, whereas BT-35 is intrinsically resistant (Kolb et al. Ped Blood Cancer, 2010). Biochemical characterization showed that MEK1/2 were equally inhibited by AZD6244 treatment in both BT-35 and BT-40 xenografts, as demonstrated by the level and duration of inhibition of phospho-ERK1/2. However, inhibition of MEK1/2 had no effect on TORC1 signaling in BT-35 (insensitive) tumors whereas in BT-40 xenografts TORC1 signaling was completely inhibited by AZD6244. The pathway through which mutant BRAF controls TORC1 signaling is currently under evaluation. However, control of TORC1 by mutant BRAF potentially exposes these cells to therapeutic exploitation. We have shown previously that the TOR kinase inhibitor AZD8055 potently suppresses FANCD2, a protein involved in interstrand cross-link (ICL) repair of DNA damage. Similar to the effect of AZD8055, within 4 days treatment of mice with AZD6244, FANCD2 levels are dramatically reduced and were no longer detected in BT-40 xenografts. Preliminary results show that inhibition of TOR signaling by AZD8055 is synergistic with daily radiation in rhabdomyosarcoma xenografts. We hypothesize that because MEK inhibition leads to suppression of TORC1 signaling and FANCD2 in BT-40 astrocytoma xenografts, that combination of AZD6244 with ionizing radiation or drugs that induce ICL will be selectively synergistic in the context of BRAF mutation. Experiments to test the hypothesis are ongoing. Supported by a Peletonia grant from the Ohio State University. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2481. doi:1538-7445.AM2012-2481
AORTIC VALVE REPAIR/REPLACEMENT SHORTENS THE PROLONGED QT INTERVAL IN PATIENTS WITH ACQUIRED LONG QT SYNDROME ASSOCIATED WITH AORTIC VALVE STENOSIS
Authors: Li Zhang, Amanulla Khaji, Zakir Shaik, Scott Goldman, Roberto Rodriguez, Lisa Igidbashian, Hafiz Khan, Eric Gnall, Paul Coady, Katie Hawthorne, Konstadinos Plestis, Peter Kowey
Journal: Journal of the American College of Cardiology (2016)
FRI0125 Comparison of characteristics of international and national databases in rheumatoid arthritis: a systematic literature review
Authors: E. Gvozdenovic, R. Koevoets, J. Langenhoff, R. Allaart, R. Landewé
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> RA cohorts and registers are established for daily practice in clinical care. Despite existing guidelines and international consensus about preferred drug therapies, there are still differences between registries in disease activity and outcome, which might be due to varying definitions for disease, inclusion criteria and variety in usage of biological agents. To improve collaboration between European rheumatologists, EULAR has recently started a repository of databases, which can be used as a platform for researchers to start collaborative projects <h3>Objectives</h3> To perform a systematic review on international, national registers and observational cohorts in Europe, to inform on participation in the EULAR repository of databases, and compare inclusion criteria, registry aim, registry type and the extent of data collection. <h3>Methods</h3> An extensive search strategy was performed in Pubmed, Embase, Web of Science (WOS), Academic Search Premier, Wiley-Blackwell and LWW. Articles reporting on European prospective cohorts in RA with at least half a year of follow-up and &gt;200 patients included were selected. We extracted data on national and international databases with details on aim, size, selection criteria, year of inception, frequency of data collection, physician/clinical evaluation, patient reported outcomes, laboratory information, funding and rheumatologic diseases captured. <h3>Results</h3> In total, 418 articles were included, which described 4 international and 39 national databases. International databases were roughly similar and are mostly initiated to monitor and compare clinical patient care among countries. Also no restriction was present in frequency of data collection and selection criteria. The national databases differ in clinical features, such as aims (Most registers aimed at efficacy and safety of treatment or monitoring disease activity in clinical practice), distribution among countries (not evenly distributed) and inclusion criteria (e.g. early RA registers versus routine care registers). Half of the national registers were connected to the EULAR repository of databases. <h3>Conclusions</h3> International registries have similar characteristics and the patients represent a large range of clinical activity (from inactive to active) and severity (from mild to severe). Regarding the national databases heterogeneity is far greater, relevant differences exist in inclusion criteria, aims, frequency of data collection and distribution among Europe. Also only half of the databases are connected to the EULAR repository of databases. These differences may indicate that among researchers there is little awareness in guidelines to set up registers or cohorts and in the existence of the collaboration network of the EULAR <h3>Disclosure of Interest</h3> None Declared
Reply to Pelosi
Authors: J.-M. Dumonceau, A. Riphaus, J. Aparicio, U. Beilenhoff, M. Ortmann, G. Paspatis, C. Ponsioen, I. Racz, F. Schreiber, P. Vilmann, T. Wehrmann, B. Walder, H. Neuhaus, and NAAP Task Force members
Journal: Endoscopy (2012)

See also: European Society of Gastrointestinal Endoscopy, European Society of Gastroenterology and Endoscopy Nurses and Associates, and the European Society of Anaesthesiology Guideline: Non-anesthesiologist administration of propofol for GI endoscopyEndoscopy 2010; 42(11): 960-974DOI: 10.1055/s-0030-1255728
Abstract 3201: PTBP1 stability is increased in ovarian and breast cancer cell lines compared to matched controls.
Authors: Ahmet Dirim Arslan, Szilard Asztalos, Martha Stampfer, Debra Tonetti, Xiaolong He, William T. Beck
Journal: Cancer Research (2013)

Abstract PTBP1 (polypyrimidine tract-binding) protein is a splicing factor that is frequently upregulated in ovarian and breast tumors. Knockdown (KD) of PTBP1 expression by shRNA impairs ovarian tumor cell growth in vivo and in vitro, as well as colony formation and invasiveness in vitro (He et al, Oncogene 26:4961-8, 2007). We have also found that PTBP1 is progressively upregulated in immortalized human mammary epithelial cells (HMECs) and human ovarian surface epithelial (HOSE) cells, correlating with their transformation state. These results prompted us to determine the factors that play a role in the upregulation of PTBP1 protein expression. We first asked whether the increased PTBP1 protein in human ovarian and breast cell lines is accompanied by proportional increases of PTBP1 mRNA. We found that there was a discordance between PTBP1 mRNA and protein levels, as measured by RT-PCR and western blot, in these cancer cell lines in relation to the control cells (finite lifespan HMEC or HOSE, respectively). Accordingly, we attempted to understand the basis for this discrepancy, and measured PTBP1 protein half-life. We treated A2780 (ovarian cancer), MCF7 (breast cancer) cells, and “finite lifespan” HMEC (184A1) with cycloheximide to terminate protein synthesis and followed the fate of PTBP1 protein over time by western blot. We found that the half-life of PTBP1 protein is ∼3-5 h in the HMECs with finite lifespan, whereas it ranges from ∼9-12h in human epithelial ovarian and breast cancer cells. These results demonstrate that PTBP1 expression is regulated in part by events that control the stability of the protein and suggest that the normal regulation of PTBP1 protein turnover is altered in cancer cell lines. Bioinformatics analysis identified one possible SUMO-binding motif site within the PTBP1 protein (SUMOsp 2.0 - SUMOylation Site Prediction, http://sumosp.biocuckoo.org/), suggesting that SUMOylation may play a role in PTBP1 stability; we are currently examining this possibility. Findings presented herein will enhance our understanding of the regulation of PTBP1 expression and the mechanisms underlying its variation in protein and mRNA levels in ovarian and breast tumors. (Support in part by NCI grants R01 CA40570 and R01 CA138762 [to WTB], by OCRF [to XH], and by UIC.) Citation Format: Ahmet Dirim Arslan, Szilard Asztalos, Martha Stampfer, Debra Tonetti, Xiaolong He, William T. Beck. PTBP1 stability is increased in ovarian and breast cancer cell lines compared to matched controls. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3201. doi:10.1158/1538-7445.AM2013-3201
Abstract 2582: 2-ME2-induced biological effects in prostate cancer: Role for miR127-3p/SET8
Authors: Jianping Xie, Izhar Singh Batth, Roble Bedolla, Guiming Li, Hung-I Harry Chen, Yidong Chen, Rita Ghosh, Addanki Pratap Kumar
Journal: Cancer Research (2012)

Abstract Prostate cancer is the second most common cause of death related to cancer in Western societies. 2-Methoxyestradiol (2-ME2), an endogenous metabolite of 17-α estradiol inhibits tumor cell proliferation in various cancer cells, including the prostate. Previous studies from our laboratory showed that 2-ME2 (i) inhibits proliferation of both androgen responsive and independent cells through induction of apoptosis involving G2/M check point block; (ii) prevents the development of prostate tumors in transgenic adenocarcinoma of mouse prostate (TRAMP) model. Although various molecular targets have been proposed, the mechanism of action behind its antiproliferative activity is still uncertain. Here we investigated the possible role for 2-ME2 induced antiproliferative activity by examining the altered regulation of microRNA (miRNAs). MicroRNA expression profiling identified miR127-3p as most significantly up regulated in response to 2-ME2 treatment in androgen independent (PC-3) cells. We have also identified histone methylase SET8 as a potential target of miR 127-3p. We have validated these data using Q-PCR. Further 2-ME2 treatment reduced binding of multiple transcription factors including Sp1, Sp3 and NFκB to the FLIP promoter as evidenced by transient expression assays, ChIP and gel-shift assays. Our findings indicate that 2-ME2 suppresses proliferation and induces apoptosis in prostate cancer cells possibly through miR127-3p/SET8 mediated regulation of FLIP. Supported by NIH CA 135451 (APK). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2582. doi:1538-7445.AM2012-2582
99mTc-Pertechnetate SPECT/CT for Detecting Recurrent Foregut Duplication Cyst in a Case With Negative Planar Scintigraphy
Authors: Punit Sharma, Harmandeep Singh, Aftab Hasan Nazar, Mudur Srinivas, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2013)

Recurrence can occur after incomplete surgical excision of foregut duplication cysts. We here present 99mTc-pertechnetate SPECT/CT images of a 3-year-old girl with recurrence of foregut duplication cyst. Planar 99mTc-pertechnetate scintigraphy was negative in this case.
FRI0109 Predicting cardiovascular disease in rheumatoid arthritis: The effect of long-term storage on measured cholesterol levels in frozen serum samples
Authors: E. Arts, J. Smith, O. Arntz, C. Popa, A.G. Semb, F. van de Loo, P. van Riel, G. Kitas, J. Fransen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Cardiovascular risk is increased in rheumatoid arthritis (RA) patients. Algorithms for cardiovascular (CV) risk stratification as SCORE or Framingham's score are used in the general population. Before they can be used for (CV) risk assessment in RA, validation by calibration and updating of these algorithms, is needed. It would be an advantage if long lasting RA cohorts could be used for this purpose. However, it is unclear if cholesterol levels in frozen serum samples can be used. There is no data available regarding the validity of cholesterol measurements in samples after long-term storage (&gt;10 years). <h3>Objectives</h3> To assess the stability of serum total cholesterol (TC), HDL- and LDL-cholesterol (HDL-c, LDL-c) over time, by estimating the effect of storage time on cholesterol levels in frozen serum samples of RA patients. <h3>Methods</h3> In the Nijmegen early RA cohort that started in 1985, non-fasting blood samples were taken annually during follow-up and stored at -20<sup>o</sup>C. After thawing in 2011, TC and HDL-c were measured enzymatically. LDL-c was calculated using the Friedewald formula. Serum samples from year 0, 1, 2, 3, 5, 7 and 10, during follow-up were used. The cohort was divided into 5 sub-cohorts, starting at 1985 up to 2009 covering 5 years of calendar time each. Per subcohort, 30 RA patients were randomly selected. The data were analyzed for differences between subcohorts in cholesterol levels using longitudinal regression (linear mixed models) while age, gender, smoking, BMI, blood pressure, statin use, DAS28 score, rheumatoid factor positivity at baseline, were considered potential confounders. <h3>Results</h3> In total, 1002 serum samples were used from 152 patients, evenly distributed across sub-cohorts, with a mean±SD age 54±13.8 years, 65% were female and 80% were rheumatoid factor positive. In all sub-cohorts, the course of cholesterol levels over time was non-linear. Age and gender were added to the regression model as covariates with BMI at baseline being the only confounder. There was a significant storage effect for LDL-c levels (p=0.047), but not for TC (fig. 1) and HDL-c (p=0.099 and p=0.175 respectively). The differences between the youngest and oldest subcohorts were -0.17 mmol/L/year for LDL-c, -0.17 mmol/L/year for TC, and -0.02 mmol/L/year for HDL-c. <h3>Conclusions</h3> There was no storage effect in frozen serum on HDL-c and TC, but there was a significant storage effect on LDL. Although the found effects per additional year of storage are small, over time this effect could accumulate to a clinically relevant change and a correction factor can adjust for this effect. Therefore, serum samples stored for longer periods of time under stable conditions can be considered suitable for cholesterol measurements. <h3>Disclosure of Interest</h3> None Declared